Irsko - angličtina - HPRA (Health Products Regulatory Authority)

csl behring gmbh - human albumin solution - solution for infusion - 20, 200 gram(s)/litre - albumin

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

octapharma limited - human plasma coagulation factor ii, human plasma coagulation factor vii, human plasma coagulation factor ix, human plasma coagulation factor x, protein c, protein s - pdr+solv for soln for inf - 500 international unit - blood coagulation factors

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

octapharma limited - human coagulation factor ii, human coagulation factor vii, human coagulation factor ix, human coagulation factor x, protein c, protein s - pdr+solv for soln for inf - 1000 international unit - blood coagulation factors

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - human coagulation factor ii; human coagulation factor vii; human coagulation factor ix; human coagulation factor x; human protein c - powder and solvent for solution for injection - coagulation factor ix, ii, vii and x in combination

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

octapharma pharmazeutika produktionsges. m.b.h. - human blood coagulation factor ii, human blood coagulation factor vii, human blood coagulation factor ix, human blood coagulation factor x, protein c, protein s - powder and solvent for solution for infusion - 14-38iu/ml+ 9-24iu/ml+ 25iu/ml+ 18-30iu/ml+ 13-31iu/ml+ 12-32iu/ml

Izrael - angličtina - Ministry of Health

csl behring ltd., israel - human fibrinogen - powder for solution for inj/inf - human fibrinogen 1800 - 2600 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

Malta - angličtina - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - immunoglobulin rabies, human - solution for injection - immunoglobulin rabies, human 150 iu/ml - immune sera and immunoglobulins

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 250 iu; human immunoglobulin g, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; human immunoglobulin a - tetanus immunoglobulin is indicated for the passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. it should also be given to the fully immunised patient with a tetanus-prone wound if more than 10 years have elapsed since the last dose of toxoid. in all the above instances, active immunisation with tetanus toxoid, adsorbed or adt vaccine should be commenced at the same time [in accordance with details specified in table 1 (guide to tetanus prophylaxis in wound management) in indication section of the approved product information provided as attachment 1]. although tetanus immunoglobulin and vaccine should be given at the same time, they should be administered in opposite limbs, using separate syringes.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 4000 iu; human immunoglobulin g, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: maltose; water for injections; human immunoglobulin a - tetanus immunoglobulin-vf (for intravenous use) is used in the management of clinical tetanus.

Malta - angličtina - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 200 g/l - blood substitutes and perfusion solutions